ArticleTransboundary and emerging diseases2026
Development of Magnetic Particle-Based Chemiluminescence Immunoassays for Detecting PCV2 VLP- and Rep-Specific Antibodies and Their Combined Use for Immune Evaluation and Replication-Associated Exposure Assessment.
Article in Transboundary and emerging diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Porcine circovirus 2 (PCV2) remains a major swine pathogen, and interpretation of capsid protein (Cap)-based serology is challenging in vaccinated populations because vaccine-induced Cap antibodies overlap with replication-associated serological signals. To address this issue, we developed two fully automated magnetic particle-based chemiluminescence immunoassays (CLIAs), including a Cap virus-like particle (VLP)-based assay (VLPs-CLIA) for evaluating Cap antibody response intensity and a replication-associated protein (Rep)-based assay (rRep-CLIA) for assessing replication-associated serological exposure or pressure. We produced self-assembled PCV2 Cap VLPs and recombinant Rep in a prokaryotic system and covalently coupled them to carboxylated magnetic beads for fully automated CLIAs. VLPs-CLIA was calibrated and reported in activity units (U), whereas rRep-CLIA was interpreted as a threshold-based qualitative assay using a relative light unit (RLU) cut-off. Analytical performance and agreement with reference enzyme-linked immunosorbent assays (ELISAs) were evaluated using longitudinal and field serum samples. VLPs-CLIA detected antibodies up to 1:25,600, approximately twofold higher than the reference ELISA (1:12,800), with 95.68% agreement (Kappa = 0.876,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.